Cargando…

New Strategies for the Treatment of Older Myeloma Patients

SIMPLE SUMMARY: While novel therapies have improved outcomes in multiple myeloma (MM), physicians are calling for greater caution when managing this hematologic malignancy in older patients due to their fragility, which increases their vulnerability to toxic events. Additionally, this patient popula...

Descripción completa

Detalles Bibliográficos
Autores principales:	Larocca, Alessandra, Cani, Lorenzo, Bertuglia, Giuseppe, Bruno, Benedetto, Bringhen, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216689/ https://www.ncbi.nlm.nih.gov/pubmed/37345030 http://dx.doi.org/10.3390/cancers15102693

Ejemplares similares

Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?
por: Bertuglia, Giuseppe, et al.
Publicado: (2022)

Emerging drugs and combinations to treat multiple myeloma
por: Larocca, Alessandra, et al.
Publicado: (2017)

The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review
por: Mian, Hira, et al.
Publicado: (2023)

Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results
por: Bertamini, Luca, et al.
Publicado: (2022)

The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2020)

Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True
por: D’Agostino, Mattia, et al.
Publicado: (2020)

Diagnostic and Therapeutic Challenges in the Management of Intermediate and Frail Elderly Multiple Myeloma Patients
por: Bonello, Francesca, et al.
Publicado: (2020)

Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma
por: Mateos, María-Victoria, et al.
Publicado: (2020)

Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)
por: Bringhen, Sara, et al.
Publicado: (2018)

Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma
por: Mian, Hira, et al.
Publicado: (2020)

Moving Toward Continuous Therapy in Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2019)

New Treatment Strategies Making an Impact in Multiple Myeloma
por: Gleason, Charise, et al.
Publicado: (2017)

Role of Allogeneic Transplantation in Multiple Myeloma in the Era of New Drugs
por: Bruno, Benedetto, et al.
Publicado: (2010)

Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma
por: Cho, Shih-Feng, et al.
Publicado: (2017)

Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting
por: Bonello, Francesca, et al.
Publicado: (2022)

Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients
por: Mingrone, Giulia, et al.
Publicado: (2021)

Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell’Adulto Multiple Myeloma Working Party study
por: Musto, Pellegrino, et al.
Publicado: (2015)

Insights on Multiple Myeloma Treatment Strategies
por: Mateos, María-Victoria, et al.
Publicado: (2018)

Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies
por: Bringhen, Sara, et al.
Publicado: (2019)

Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments
por: Cancanelli, Luca, et al.
Publicado: (2023)

P1680: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH FIXED-DURATION BORTEZOMIB-MELPHALAN-PREDNISONE VS. CONTINUOUS LENALIDOMIDE-DEXAMETHASONE
por: D’agostino, Mattia, et al.
Publicado: (2023)

New insights in lower limb reconstruction strategies
por: Toro, Giuseppe, et al.
Publicado: (2023)

Cardiovascular Organ Damage and Blood Pressure Levels Predict Adverse Events in Multiple Myeloma Patients Undergoing Carfilzomib Therapy
por: Bruno, Giulia, et al.
Publicado: (2019)

Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events Prediction
por: Astarita, Anna, et al.
Publicado: (2021)

Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial
por: Saltarella, Ilaria, et al.
Publicado: (2019)

Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies
por: Vallet, Sonia, et al.
Publicado: (2018)

Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial
por: Bringhen, Sara, et al.
Publicado: (2020)

Evolving treatment strategies for myeloma
por: Morgan, G J, et al.
Publicado: (2005)

New Frontiers in the Treatment of Multiple Myeloma
por: Hwang, Janice Jin, et al.
Publicado: (2006)

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials
por: Larocca, Alessandra, et al.
Publicado: (2020)

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2020)

New agents in the Treatment of Myeloma Bone Disease
por: Ring, Elizabeth S., et al.
Publicado: (2017)

What Is New in the Treatment of Smoldering Multiple Myeloma?
por: Bolli, Niccolo’, et al.
Publicado: (2021)

Treatment of Myelofibrosis: Old and New Strategies
por: Iurlo, Alessandra, et al.
Publicado: (2017)

Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score
por: D’Agostino, Mattia, et al.
Publicado: (2021)

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2020)

Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple Myeloma
por: Suzuki, Kazuhito, et al.
Publicado: (2021)

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
por: Nijhof, Inger S., et al.
Publicado: (2017)

Current and Emerging Treatment Options for Patients with Relapsed Myeloma
por: Castelli, Roberto, et al.
Publicado: (2013)

Immunotherapy Strategies Against Multiple Myeloma
por: Ma, Jing, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2rrv0b6mlfc11cmta4cqut182n